Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method
Open Access
- 1 January 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (1) , 103-107
- https://doi.org/10.1128/aac.33.1.103
Abstract
The increasing resistance of genital mycoplasmas to tetracycline poses a problem because tetracycline is one of the few antimicrobial agents active against Mycoplasma hominis, Ureaplasma urealyticum, chlamydiae, gonococci, and other agents of genitourinary-tract disease. Since the quinolones are a promising group of antimicrobial agents, the susceptibilities of M. hominis and U. urealyticum to the newer 6-fluoroquinolones were determined by the agar dilution method. Ciprofloxacin, difloxacin, and ofloxacin had good activity against M. hominis, with the MIC for 50% of isolates tested (MIC50) being 1 microgram/ml. Fleroxacin, lomefloxacin, pefloxacin, and rosoxacin had MIC50s of 2 micrograms/ml. Enoxacin, norfloxacin, and amifloxacin had MIC50s of 8 to 16 micrograms/ml, and cinoxacin and nalidixic acid were inactive (MIC50, greater than or equal to 256 micrograms/ml). Overall, the activities of 6-fluoroquinolones for ureaplasmas were similar to those for M. hominis, with MICs being the same or twofold greater. The most active 6-fluoroquinolones against ureaplasmas were difloxacin, ofloxacin, and pefloxacin, with MIC50s of 1 to 2 micrograms/ml. Ciprofloxacin was unusual in that the MIC50 for M. hominis was 1 microgram/ml, whereas the MIC50 for ureaplasmas was 8 micrograms/ml. Since the MIC50s for the most active quinolones approximate achievable concentrations in blood and urine, quinolones have promise in treating mycoplasmal infections.This publication has 26 references indexed in Scilit:
- Characterization of tetracycline-resistant strains of Ureaplasma urealyticumJournal of Antimicrobial Chemotherapy, 1988
- The Quinolones: An Overview and Comparative Appraisal of Their Pharmacokinetics and PharmacodynamicsThe Journal of Clinical Pharmacology, 1988
- Mode of Action, and In Vitro and In Vivo Activities of the FluoroquinolonesThe Journal of Clinical Pharmacology, 1988
- Ciprofloxacin treatment of chlamydial infections of urogenital tracts of women.Sexually Transmitted Infections, 1988
- In vitro activity of the two new 4-quinolones A56619 and A56620 againstNeisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum andGardnerella vaginalisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- Clinical experience with ciprofloxacin in the USAEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- In vitro activity of amifloxacin againstChlamydia trachomatis andUreaplasma urealyticumEuropean Journal of Clinical Microbiology & Infectious Diseases, 1985
- In-vitro sesisitivity of legionellas, meningococci and mycoplasinas to ciprofloxacin and enoxacinJournal of Antimicrobial Chemotherapy, 1985
- The activity of ciprofloxacin and other 4-quinolones againstChlamydia trachomatis andMycoplasmas in vitroEuropean Journal of Clinical Microbiology & Infectious Diseases, 1984
- Minocycline Resistance among Clinical Isolates of Ureaplasma urealyticumThe Journal of Infectious Diseases, 1984